4/23
08:04 am
pdsb
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer [Yahoo! Finance]
Medium
Report
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer [Yahoo! Finance]
4/23
08:00 am
pdsb
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
High
Report
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
3/30
09:01 am
pdsb
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions [Yahoo! Finance]
Low
Report
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions [Yahoo! Finance]
3/28
10:34 am
pdsb
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
10:57 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
3/27
07:39 am
pdsb
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/27
07:30 am
pdsb
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
High
Report
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
3/21
11:58 am
pdsb
NetScientific: Significant Advancement with Strategic Goals [Yahoo! Finance]
Low
Report
NetScientific: Significant Advancement with Strategic Goals [Yahoo! Finance]
3/20
08:11 am
pdsb
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results [Yahoo! Finance]
3/20
08:00 am
pdsb
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
Low
Report
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
3/16
02:05 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/13
08:00 am
pdsb
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Low
Report
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
3/8
11:04 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
PDS Biotechnology Co. (NASDAQ: PDSB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.